Aflibercept
Indication
Wet age-related macular degeneration (NICE TA294)
NICE TA294 - Aflibercept solution for injection for treating wet age‑related macular degeneration
Red
Brand:
Eylea ®
Nice TA:
294
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Eye
Background
Aflibercept solution for injection is recommended as an option for treating wet age-related macular degeneration only if:
- it is used in accordance with the recommendations for ranibizumab in NICE technology appraisal guidance 155 (re-issued in May 2012) and
- the manufacturer provides aflibercept solution for injection with the discount agreed in the patient access scheme.